CureVac BV (CVAC) Stock Price Today
24H
1W
1M
3M
YTD
1Y
5Y
Overview
Financial
Technicals
Analysis
Corporate Action
About
About CureVac BV
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Technical Indicators
|
|
|
Overall Summary
Bearish (12)
Neutral (5)
Bullish (10)
Performance
CVAC ROI
+54.94%
% from 52W High
-4.82%
52W Low: $2.49
19 Nov 2024
52W High: $5.6
12 Jun 2025
News
US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions
